# Porton Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/porton-biologics

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.portonbio.com
- Total disclosed funding: $138M
- Latest round: Series B (Aug 19, 2022)
- Investors on record: 12

## About

Established in 2018 and based in Suzhou, China, Porton Biologics Ltd. is a contract development and manufacturing organization(CDMO). The company is a ranch office of Chongqing Porton Fine Chemicals Co., Ltd., which is listed on the Shenzhen Stock Exchange. The company is located in Suzhou Industrial Park, with a building area of about 5000 square meters. It has GMP process scale-up and pilot production workshops and CAR-T cell amplification laboratories designed and built according to cGMP, FDA, EU-GMP and NMPA standards.

The company provides gene and cell therapy CDMO services and has built a CDMO platform that integrates plasmids, cell therapy, gene therapy, lytic virus, nucleic acid therapy and live bacteriophage therapy, and is able to provide customers with services to analyze and test data. These include protein quantification, physicochemical analysis, etc.

The company raised a series B funding in August 2022, this round of funding will be used to accelerate the refinement of the end-to-end gene and cell therapy (GCT) CDMO platform.

## Funding rounds

- Series B, Aug 19, 2022, $76M — Chongqing Porton Fine Chemicals Co., Ltd., China Merchants Capital, China Merchants Securities, Huashan Ruilian Fund Management, CS Capital, Gortune Investment, SDIC Taikang Trust, HM Capital, Shijie Investment, Fosun Health Capital, China Merchants Health Industry Holdings
- Series A, Apr 16, 2021, $62M — CS Capital, Huashan Ruilian Fund Management, GL Ventures, HM Capital, Shijie Investment

## Investors

- CS Capital — Series A, Series B
- Huashan Ruilian Fund Management (https://capitalatlas.ai/funds/huashan-ruilian-fund-management) — Series A, Series B
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series A
- HM Capital (https://capitalatlas.ai/funds/hm-capital) — Series A, Series B
- Shijie Investment (https://capitalatlas.ai/funds/shijie-investment) — Series A, Series B
- Chongqing Porton Fine Chemicals Co., Ltd. — Series B
- China Merchants Capital (https://capitalatlas.ai/funds/china-merchants-capital) — Series B
- China Merchants Securities — Series B
- Gortune Investment (https://capitalatlas.ai/funds/gortune-investment) — Series B
- SDIC Taikang Trust — Series B
- Fosun Health Capital (https://capitalatlas.ai/funds/fosun-health-capital) — Series B
- China Merchants Health Industry Holdings — Series B